Psyence Biomedical Ltd. (PBM)

CA — Healthcare Sector

Peers: AZTR NKGN GTBP REVB PTIX LIPO ELAB SPRC DRMA INDP

Automate Your Wheel Strategy on PBM

With Tiblio's Option Bot, you can configure your own wheel strategy including PBM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol PBM
Rev/Share 0.0
Book/Share 8.01
PB 0.0999
Debt/Equity 0.0
CurrentRatio 8.09
ROIC -0.2244

MktCap 570586.0
FreeCF/Share 0.0
PFCF 0.0
PE -1.9373
Debt/Assets 0.0
DivYield 0
ROE -0.1153

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 5
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

PBM
Published: January 05, 2026 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement.

image for news Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

PBM
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral

New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.

image for news Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

PBM, PSYGF
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D.

image for news Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

PBM
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.

image for news Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

About Psyence Biomedical Ltd. (PBM)

IPO Date 2021-12-10
Website https://www.psyencebiomed.com
Industry Biotechnology
CEO Jody Aufrichtig
Employees 10

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.